# **ILLS 2023 Clinical data**

# IRE – PANCREAS

**- Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas**

Dunki-Jacobs et al. - Journal of the American College of Surgeons. 2014;218(2):179-87.

<http://dx.doi.org/10.1016/j.jamcollsurg.2013.10.013>

**- Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma**

P. Marsanic et al. - Med Biol Eng Comput 2017 Jul;55(7):1123-1127.

DOI 10.1007/s11517-016-1603-9

**- The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma**

Hung et al. - Journal of surgical oncology. 2018;118(1):31-6.

DOI: 10.1002/jso.25110

**- A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry**

Holland et al. - HPB. 2019;21(8):1024-31.

<https://doi.org/10.1016/j.hpb.2018.12.004>

**- Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer**

Lafranceschina et al. - Cancers 2019, 11, 1718.

doi:10.3390/cancers11111718

**- Application of Irreversible Electroporation Ablation as adjunctive treatment for Margin Enhancement: Safety and Efficacy**

Simmerman et al. - J Surg Res. 2020 Feb;246:260-268.

doi: 10.1016/j.jss.2019.06.010

**- Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer**

He et al. – Front. Oncol., Feb 2021 Sec. Surgical Onology VOL.10-2020.

doi: 10.3389/fonc.2020.622318

**- Irreversible Electroporation of locally advances pancreatic cancer**

Kwon et al. - Seminars in Oncology 2021, Pages 84-94.

https://doi.org/10.1053/j.seminoncol.2021.02.004

**- Ablation in Pancreatic Cancer: Past, Present and Future**

Govindarajan Narayanan et al. - Cancers 2021, 13, 2511.

https://doi.org/10.3390/cancers13112511

**- Irreversible electroporation for the management of pancreatic cancer: Current data and future directions**

Spiliopoulos et al. - World J Gastroenterol 2023 January 14; 29(2): 223-231.

DOI: 10.3748/wjg.v29.i2.223

# IRE - PANCREAS – Margin Accentuation

**- Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation**

Papoulas et al. - Journal of Surgical Case Reports, 2018;6, 1–4.

doi: 10.1093/jscr/rjy127

**- Margin Accentuation Irreversible Electroporation in Stage III Pancreatic Cancer: A Systematic Review**

Ratnayake et al. - Cancers 2021, 13, 3212.

<https://doi.org/10.3390/cancers13133212>

**- Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation e Results from the MACPIE-I study**

Kundalia, Menon et al. – European Journal of Surgical Oncology 2021, p.2571-2578.

<https://doi.org/10.1016/j.ejso.2021.05.024>

**- Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer**

Martin et al. - Surgery 173 (2023) 581e589.

<https://doi.org/10.1016/j.surg.2022.07.033>

# IRE - PANCREAS – Immunotherapy

**- Irreversible Electroporation for Locally Advanced Pancreatic Cancer**

Timmer et al. - Tech Vasc Interv Radiol. 2020 Jun;23(2):100675.

doi: 10.1016/j.tvir.2020.100675

**- Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival**

Timmer et al. – JVIR 2023, online June 2023.

https://doi.org/10.1016/j.jvir.2023.06.027

# IRE - PANCREAS – Neuroendocrine Tumors

**- Non‐surgical ablative therapies for inoperable benign insulinoma**

C. Mele et al. - J Endocrinol Invest (2018) 41:153–162.

<https://doi.org/10.1007/s40618-017-0738-3>

**- Percutaneous irreversible electroporation for the treatment of pancreatic insulinoma**

Tasu et al. - Diagnostic andInterventionalImaging104(2023)307−308.

<https://doi.org/10.1016/j.diii.2023.03.006>